187 related articles for article (PubMed ID: 35111385)
1. Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Bendtsen SK; Perez-Penco M; Hübbe ML; Martinenaite E; Orebo Holmström M; Weis-Banke SE; Grønne Dahlager Jørgensen N; Jørgensen MA; Munir Ahmad S; Jensen KM; Friese C; Lundsager MT; Johansen AZ; Carretta M; Ødum N; Met Ö; Svane IM; Madsen DH; Andersen MH
Oncoimmunology; 2022; 11(1):2026020. PubMed ID: 35111385
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases.
Fan Y; Song S; Li Y; Dhar SS; Jin J; Yoshimura K; Yao X; Wang R; Scott AW; Pizzi MP; Wu J; Ma L; Calin GA; Hanash S; Wang L; Curran M; Ajani JA
Cancer Res; 2023 Nov; 83(22):3726-3738. PubMed ID: 37738407
[TBL] [Abstract][Full Text] [Related]
3. TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor.
Raiter A; Lipovetsky J; Stenbac A; Lubin I; Yerushalmi R
Oncoimmunology; 2023; 12(1):2246322. PubMed ID: 37593677
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling.
Zhao W; Ajani JA; Sushovan G; Ochi N; Hwang R; Hafley M; Johnson RL; Bresalier RS; Logsdon CD; Zhang Z; Song S
Gastroenterology; 2018 Apr; 154(5):1524-1537.e6. PubMed ID: 29274868
[TBL] [Abstract][Full Text] [Related]
5. Galectin 3 expression in primary oral squamous cell carcinomas.
Weber M; Büttner-Herold M; Distel L; Ries J; Moebius P; Preidl R; Geppert CI; Neukam FW; Wehrhan F
BMC Cancer; 2017 Dec; 17(1):906. PubMed ID: 29284429
[TBL] [Abstract][Full Text] [Related]
6. Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity.
Bernardes ES; Silva NM; Ruas LP; Mineo JR; Loyola AM; Hsu DK; Liu FT; Chammas R; Roque-Barreira MC
Am J Pathol; 2006 Jun; 168(6):1910-20. PubMed ID: 16723706
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 is critical for the development of the allergic inflammatory response in a mouse model of atopic dermatitis.
Saegusa J; Hsu DK; Chen HY; Yu L; Fermin A; Fung MA; Liu FT
Am J Pathol; 2009 Mar; 174(3):922-31. PubMed ID: 19179612
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors.
Jia W; Kidoya H; Yamakawa D; Naito H; Takakura N
Am J Pathol; 2013 May; 182(5):1821-31. PubMed ID: 23499465
[TBL] [Abstract][Full Text] [Related]
9. A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma.
Liebscher L; Weißenborn C; Langwisch S; Gohlke BO; Preissner R; Rabinovich GA; Christiansen N; Christiansen H; Zenclussen AC; Fest S
Cancer Lett; 2021 Jul; 509():105-114. PubMed ID: 33848518
[TBL] [Abstract][Full Text] [Related]
10. Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas.
Wehrhan F; Büttner-Herold M; Distel L; Ries J; Moebius P; Preidl R; Geppert CI; Neukam FW; Kesting M; Weber M
BMC Cancer; 2018 Aug; 18(1):823. PubMed ID: 30115022
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.
Herrador-Cañete G; Zalacain M; Labiano S; Laspidea V; Puigdelloses M; Marrodan L; Garcia-Moure M; Gonzalez-Huarriz M; Marco-Sanz J; Ausejo-Mauleon I; de la Nava D; Hernández-Osuna R; Martínez-García J; Silva-Pilipich N; Gurucega E; Patiño-García A; Hernández-Alcoceba R; Smerdou C; Alonso MM
Mol Ther Oncolytics; 2022 Sep; 26():246-264. PubMed ID: 35949950
[TBL] [Abstract][Full Text] [Related]
12. Lack of galectin-3 alters the balance of innate immune cytokines and confers resistance to Rhodococcus equi infection.
Ferraz LC; Bernardes ES; Oliveira AF; Ruas LP; Fermino ML; Soares SG; Loyola AM; Oliver C; Jamur MC; Hsu DK; Liu FT; Chammas R; Roque-Barreira MC
Eur J Immunol; 2008 Oct; 38(10):2762-75. PubMed ID: 18825751
[TBL] [Abstract][Full Text] [Related]
13. The inactive form of glycogen synthase kinase-3β is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice.
Mendonça DF; Chammas R; Liu FT; Nonogaki S; Cardoso SV; Loyola AM; de Faria PR
Int J Clin Exp Pathol; 2012; 5(6):547-54. PubMed ID: 22949937
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 modulation of T-cell activation: mechanisms of membrane remodelling.
Gilson RC; Gunasinghe SD; Johannes L; Gaus K
Prog Lipid Res; 2019 Oct; 76():101010. PubMed ID: 31682868
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 regulates inflammasome activation in cholestatic liver injury.
Tian J; Yang G; Chen HY; Hsu DK; Tomilov A; Olson KA; Dehnad A; Fish SR; Cortopassi G; Zhao B; Liu FT; Gershwin ME; Török NJ; Jiang JX
FASEB J; 2016 Dec; 30(12):4202-4213. PubMed ID: 27630169
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 mediates survival and apoptosis pathways during Trypanosoma cruzi-host cell interplay.
Chain MO; Paiva CAM; Maciel IO; Neto AN; Castro VF; Oliveira CP; Mendonça BDS; Nestal de Moraes G; Reis SAD; Carvalho MA; De-Melo LDB
Exp Parasitol; 2020 Sep; 216():107932. PubMed ID: 32535113
[TBL] [Abstract][Full Text] [Related]
18. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis.
Guha P; Kaptan E; Bandyopadhyaya G; Kaczanowska S; Davila E; Thompson K; Martin SS; Kalvakolanu DV; Vasta GR; Ahmed H
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5052-7. PubMed ID: 23479624
[TBL] [Abstract][Full Text] [Related]
19. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
